HCPCS Q-Codes
Miscellaneous Services (Temporary Codes)

CMS assigns Q codes to procedures, services, and supplies on a temporary basis. When a permanent code is assigned, the Q code is deleted and cross-referenced.

  • Q0035

    Cardiokymography

  • Q0081

    Infusion therapy, using other than chemotherapeutic drugs, per visit

  • Q0083

    Chemotherapy administration by other than infusion technique only (e.g., subcutaneous, intramuscular, push), per visit

  • Q0084

    Chemotherapy administration by infusion technique only, per visit

  • Q0085

    Chemotherapy administration by both infusion technique and other technique(s) (e.g., subcutaneous, intramuscular, push), per visit

  • Q0091

    Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory

  • Q0092

    Set-up portable x-ray equipment

  • Q0111

    Wet mounts, including preparations of vaginal, cervical or skin specimens

  • Q0112

    All potassium hydroxide (koh) preparations

  • Q0113

    Pinworm examinations
  • Continued

  • Q0114

    Fern test

  • Q0115

    Post-coital direct, qualitative examinations of vaginal or cervical mucous

  • Q0138

    Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)

  • Q0139

    Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)

  • Q0144

    Azithromycin dihydrate, oral, capsules/powder, 1 gram

  • Q0161

    Chlorpromazine hydrochloride, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

  • Q0162

    Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

  • Q0163

    Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen

  • Q0164

    Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

  • Q0166

    Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen

  • Q0167

    Dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

  • Q0169

    Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

  • Q0173

    Trimethobenzamide hydrochloride, 250 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

  • Q0174

    Thiethylperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

  • Q0175

    Perphenazine, 4 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

  • Q0177

    Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

  • Q0180

    Dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen

  • Q0181

    Unspecified oral dosage form, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for a iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

  • Q0220

    Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg

  • Q0221

    Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg
  • Continued

  • Q0222

    Injection, bebtelovimab, 175 mg

  • Q0239

    Injection, bamlanivimab-xxxx, 700 mg

  • Q0240

    Injection, casirivimab and imdevimab, 600 mg

  • Q0243

    Injection, casirivimab and imdevimab, 2400 mg

  • Q0244

    Injection, casirivimab and imdevimab, 1200 mg

  • Q0245

    Injection, bamlanivimab and etesevimab, 2100 mg

  • Q0247

    Injection, sotrovimab, 500 mg

  • Q0249

    Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg

  • Q0477

    Power module patient cable for use with electric or electric/pneumatic ventricular assist device, replacement only

  • Q0478

    Power adapter for use with electric or electric/pneumatic ventricular assist device, vehicle type

  • Q0479

    Power module for use with electric or electric/pneumatic ventricular assist device, replacement only

  • Q0480

    Driver for use with pneumatic ventricular assist device, replacement only

  • Q0481

    Microprocessor control unit for use with electric ventricular assist device, replacement only

  • Q0482

    Microprocessor control unit for use with electric/pneumatic combination ventricular assist device, replacement only

  • Q0483

    Monitor/display module for use with electric ventricular assist device, replacement only

  • Q0484

    Monitor/display module for use with electric or electric/pneumatic ventricular assist device, replacement only

  • Q0485

    Monitor control cable for use with electric ventricular assist device, replacement only

  • Q0486

    Monitor control cable for use with electric/pneumatic ventricular assist device, replacement only

  • Q0487

    Leads (pneumatic/electrical) for use with any type electric/pneumatic ventricular assist device, replacement only

  • Q0488

    Power pack base for use with electric ventricular assist device, replacement only